HC Wainwright & Co. Maintains Buy Rating for Ikena Oncology, Raises Price Target To $26

HC Wainwright & Co. has decided to maintain its Buy rating of Ikena Oncology IKNA and raise its price target from $25.00 to $26.00.

Shares of Ikena Oncology are trading up 7.06% over the last 24 hours, at $7.28 per share.

A move to $26.00 would account for a 257.14% increase from the current share price.

About Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.